WASHINGTON — The Biosimilars Council, representing leading developers of biosimilar medicines, strongly supports the reintroduction, and encourages swift passage, of the bipartisan BIOSIM Act (HR 2815). This bill is an important step toward giving Americans greater access to lifesaving, affordable medicines.
Christine Simmon, executive director of the Biosimilars Council, said, Every day, biosimilars help patients treat serious chronic illnesses at 30% lower cost than brand-name biologics. However, systemic barriers are preventing many patients from accessing these treatments, keeping prescription spending high.
Simmon continued, The bipartisan BIOSIM Act will address one of these barriers. By modestly boosting reimbursement to health care providers using biosimilars, the BIOSIM Act will encourage faster adoption of these novel treatments and deliver savings for providers and patients.
The Biosimilars Council applauds Reps. Kurt Schrader (D, Ore.) and Adam Kinzinger (R, Ill.) for fighting to expand patient access to affordable drugs, and we look forward to working with them to advance this legislation to law.
Comments are closed.